ArticleRegenerative biomaterials2026
Strontium-baicalein coated β-tricalcium phosphate scaffold enhances diabetic bone regeneration via synergistic ROS scavenging and osteogenic activation.
Article in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional bone repair materials, such as β-tricalcium phosphate (β-TCP) scaffolds, are widely used in orthopedic applications due to their excellent biocompatibility and osteoconductivity. However, their regenerative efficacy is markedly compromised under diabetic microenvironments, as they lack the ability to counteract persistent oxidative stress and hyperglycemia-induced impairment of osteogenic activity. To address this limitation, we developed a strontium-baicalein (SrB) coated β-TCP scaffold (β-TCP@SrB) with integrated antioxidative and osteoinductive functions. In this system, baicalein provides robust cytoprotective and reactive oxygen species (ROS) scavenging effects under high-glucose (HG) conditions. Meanwhile, its polyphenolic structure enables strong interfacial adhesion to β-TCP and coordination-driven assembly with Sr
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.